STANDALONE For The For Half Year Corresponding Quarter ended 30- ended For The Preceding Quarter ended

Transcription

1 DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED CIN : L24230GJ1983PLC ID : dishman@dishmangroup.com Web : Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad Phone No : Fax No : Part I : Statement of Standalone / Consolidated Unaudited Results for Quarter and Half year Ended Sr. No. PARTICULARS For The Quarter For The Preceding Quarter STANDALONE For The For Half Year Corresponding Quarter For Corresponding Half Year (Rupees in Lacs) For the Year Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Income From Operations a) Net sales/income from operations (Net of excise duty) 9, , , , , , b) Other Operating Income , Total Income from operations (net) 10, , , , , , Expenses a) Cost of material consumed 4, , , , , , b) Purchase of stock-in-trade , c) Changes in inventories of finished goods, work-inprogress and stock-in-trade (229.19) 1, (1,013.99) (2,539.88) (2,269.23) d) Power & Fuel , , , e) Employee benefits expense 1, , , , , , f) Depreciation and amortisation expense 1, , , , , g) Other Expenditure , , , , , Total expenses 8, , , , , , Profit / (Loss) from Operations before Other Income, finance costs and exceptional items (1-2) 1, , , , , , Other Income 4, , , , , Profit / (Loss) from ordinary activities before finance 6, , , , , , costs and exceptional items (3+4) 6 Finance costs 1, , , , , , Profit/(Loss) from ordinary activities after finance costs 5, , , , , , but before exceptional items (5-6) 8 Exceptional Items - 9 Profit/(Loss) from Ordinary Activities before tax (7+8) 5, , , , , , Tax expense 1, , , , Net Profit/(Loss) from Ordinary Activities after tax (9-10) 3, , , , , Extraordinary Items (net of tax expense) 13 Net Profit/(Loss) for the period (11-12) 3, , , , , Income from Associates - 15 Minority Interest - 16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates ( ) 3, , , , ,847.83

2 17 Paid -up Equity Share Capital (Face Value of Rs 2/- per equity share) 1, , , , , , , Reserves Excluding Revaluation Reserves as per balance sheet of previous accounting year 19 Basic and Diluted EPS (before & after Extraordinary Items) ( - - of Rs. 2 each) i) Basic EPS ( Not annualised) ii) Diluted EPS ( Not annualised) Debt Service Coverage Ratio (Earnings before Interest and Tax/ (Interest + Principal Repayment)) 21 Interest Service Coverage Ratio (Earnings before Interest and Tax / Interest Expense) See accompanying notes to the financial results Part II : Select Information for the Quarter A PARTICULARS OF SHAREHOLDING 1 Public Shareholding - Number of Equity Shares 31,148,687 31,148,687 31,148,687 31,148,687 31,148,687 31,148,687 - Percentage of Shareholding 38.60% 38.60% 38.60% 38.60% 38.60% 38.60% 2 Promoters and promoter group Shareholding a) Pledged/Encumbured - Number of Shares 5,676,500 8,554,000 17,776,500 5,676,500 17,776,500 15,016, % 17.26% 35.88% 11.46% 35.88% 30.31% 7.03% 10.60% 22.03% 7.03% 22.03% 18.61% b) Non-encumbured - Number of Shares 43,871,949 40,994,449 31,771,949 43,871,949 31,771,949 34,531, % 82.74% 64.12% 88.54% 64.12% 69.69% 54.37% 50.80% 39.37% 54.37% 39.37% 42.79% B INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the quarter Disposed during the quarter Remaining unresolved at the end of the quarter Quarter Fo Date: 29th October, 2015 Ar M

3 DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED CIN : L24230GJ1983PLC ID : dishman@dishm Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahm Part I : Statement of Standalone / Consolidated Unaudited Res Sr. No. PARTICULARS For The Quarter For The Preceding Quarter For The Corresponding Quarter CONSOLIDATED For Half Year For Corresponding Half Year (Rupees in Lacs) For the Year Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Income From Operations a) Net sales/income from operations (Net of excise duty) b) Other Operating Income Total Income from operations (net) 2 Expenses a) Cost of material consumed b) Purchase of stock-in-trade c) Changes in inventories of finished goods, work-inprogress and stock-in-trade d) Power & Fuel e) Employee benefits expense f) Depreciation and amortisation expense g) Other Expenditure Total expenses 3 Profit / (Loss) from Operations before Other Income, finance costs and exceptional items (1-2) 37, , , , , , , , , , , , , , , , , , , , , , , (1,905.97) 2, (1,602.44) (6,293.98) (4,259.00) , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Other Income 5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4) 6 Finance costs 7 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6) 8 Exceptional Items 9 Profit/(Loss) from Ordinary Activities before tax (7+8) 10 Tax expense 11 Net Profit/(Loss) from Ordinary Activities after tax (9-10) 12 Extraordinary Items (net of tax expense) 13 Net Profit/(Loss) for the period (11-12) 14 Income from Associates 15 Minority Interest 16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates ( ) , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , (0.18) , , , , , ,980.90

4 17 Paid -up Equity Share Capital (Face Value of Rs 2/- per equity share) 18 Reserves Excluding Revaluation Reserves as per balance sheet of previous accounting year 19 Basic and Diluted EPS (before & after Extraordinary Items) ( of Rs. 2 each) i) Basic EPS ( Not annualised) ii) Diluted EPS ( Not annualised) 20 Debt Service Coverage Ratio (Earnings before Interest and Tax/ (Interest + Principal Repayment)) 21 Interest Service Coverage Ratio (Earnings before Interest and Tax / Interest Expense) See accompanying notes to the financial results Part II : Select Information for the Quarter A PARTICULARS OF SHAREHOLDING 1 Public Shareholding - Number of Equity Shares - Percentage of Shareholding 2 Promoters and promoter group Shareholding a) Pledged/Encumbured - Number of Shares b) Non-encumbured - Number of Shares 1, , , , , , , ,148,687 31,148,687 31,148,687 31,148,687 31,148,687 31,148, % 38.60% 38.60% 38.60% 38.60% 38.60% 5,676,500 8,554,000 17,776,500 5,676,500 17,776,500 15,016, % 17.26% 35.88% 11.46% 35.88% 30.31% 7.03% 10.60% 22.03% 7.03% 22.03% 18.61% ,871,949 40,994,449 31,771,949 43,871,949 31,771,949 34,531, % 82.74% 64.12% 88.54% 64.12% 69.69% 54.37% 50.80% 39.37% 54.37% 39.37% 42.79% B INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the quarter Disposed during the quarter Remaining unresolved at the end of the quarter Quarter or and on behalf of the Board Date: 29th October, 2015 rpit Vyas Managing Director and CFO

5 Sr. No Segment wise Revenue, Result and Capital Employed PARTICULARS 1 Segment Revenue (a) CRAMS (b) Others Total Less: Inter-segment Revenue Net Sales /Income from Operation 2 Segment Results {Profit/(Loss) before tax and interest from each segment} (a) CRAMS* (b) Others* Total Less: i) Interest ii) Other un-allocable expenditure net off un-allocable income Total Profit/(Loss) Before Tax 3 Capital Employed (Segment Assets-Segment liabilities) (a) CRAMS (b) Others (c) Unallocable Total * Includes Forex (Loss) / Gain For The Quarter For The Preceding Quarter For The Corresponding Quarter For Half Year For Corresponding Half Year For the Year Unaudited Unaudited Unaudited Unaudited Unaudited Audited 26, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , (749.28) (411.80) (1,316.45) (1,161.08) (555.64) (8,608.61) 4, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , For and on behalf of the Board Date: 29th October, 2015 Arpit Vyas Managing Director and CFO

6 DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED CIN : L24230GJ1983PLC Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad Part I : Statement of Standalone / Consolidated Unudited Results As At Balance Sheet as at 30th September, 2015 Particulars STANDALONE As at As at (Rupees in Lacs) CONSOLIDATED As at As at A EQUITY AND LIABILITIES 1 Shareholders funds (a) Share capital 1, , , , (b) Reserves and surplus 87, , , , , , , , Non-current liabilities (a) Long-term borrowings 30, , , , (b) Deferred tax liabilities (net) 7, , , , (c) Other long-term liabilities (d) Long-term provisions , , , , , , Current liabilities (a) Short-term borrowings 21, , , , (b) Trade payables 8, , , , (c) Other current liabilities 10, , , , (d) Short-term provisions 2, , , , , , , , , , , , B ASSETS 1 Non-current assets (a) Fixed assets 70, , , , (b) Goodwill on Consolidation 1, , (c) Non-current investments 23, , , , (d) Long-term loans and advances 24, , , , (e) Other non-current assets , , , , Current assets (a) Current Investment 1, , , , (b) Inventories 15, , , , (c) Trade receivables 8, , , , (d) Cash and cash equivalents 1, , , , (e) Short-term loans and advances 22, , , , (f) Other current assets 2, , , , , , , , , , ,893.57

7 Notes: 1. The Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 29 th October, Joint Statutory Auditors have carried out a Limited review of the standalone financial result of the Company for the quarter 30 th September, Details of Number of Investor complaints for the quarter 30 th September, 2015: beginning - NIL, received-, resolved, pending- NIL as at 30 th September, 2015; 4. The figures have been re-grouped, re-cast and re-arranged wherever necessary; 5. As per clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The standalone financial results are available for perusal on the Company s website as well as on the stock exchanges websites as stated below: and 6. As per Accounting Standard (AS) 17 Segment Reporting, segment information has been provided in Consolidated Financial Results 7. The business segments of the Company comprise the followings: Segment CRAMS OTHERS Description of the activity Contract Research and Manufacturing Segment under long term supply agreements Bulk Drugs, Intermediates, Quats, Speciality Chemicals and Traded Goods 8. Consolidated financial results comprise the results of the parent Company, Dishman Pharmaceuticals and Chemicals Limited and its subsidiaries viz. Dishman Europe Limited., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd., Dishman Switzerland Limited, Dishman Pharma Solutions AG, Switzerland, CARBOGEN AMCIS (Shanghai) Co. Ltd. [formerly known as Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd.], Shanghai Yiqian International Trade Co., Ltd., Innovative Ozone Services Inc. (IO3S), Dishman Netherlands B. V. (formerly known as Pharma Syn B. V. ), Cohecie Fine Chemicals B.V. (formerly known as Dishman Holland B.V. ), Carbogen Amcis Ltd.,U.K. (formerly known as Synprotec DCR Ltd. ), CARBOGEN AMCIS AG, Carbogen Amcis (India) Limited, Dishman Australasia Pty. Ltd., Dishman Care Ltd., CARBOGEN AMCIS SAS, Dishman Middle East (FZE), Dishman Japan Limited, one joint venture Company, namely Schutz Dishman Biotech Ltd.(22.33% holding by Dishman), and one associate company namely, Bhadr-Raj Holdings Pvt. Ltd. (40% holding by Dishman) as per relevant Accounting Standards. On behalf of the Board of Directors Date: 29 th October, 2015 Arpit Vyas Managing Director & CFO